Chronic kidney disease (CKD) is a major global health concern characterized by a gradual and irreversible decline in renal structure and function.1 It is defined by persistent abnormalities in kidney function, structural damage, or a decreased glomerular filtration rate (GFR) lasting for more than three months.2 CKD often progresses silently in its early stages, eventually leading to end-stage renal disease (ESRD), which requires dialysis or kidney transplantation for survival.3 The increasing prevalence of CKD is strongly associated with rising rates of diabetes mellitus, hypertension, obesity, and aging populations, making it a significant burden on healthcare systems worldwide.4

The kidneys play a central role in maintaining homeostasis through regulation of fluid and electrolyte balance, acid–base equilibrium, blood pressure control, and endocrine functions such as erythropoietin production and activation of vitamin D.5 Structurally, each kidney contains approximately one million nephrons, which serve as the functional units responsible for filtration, reabsorption, secretion, and excretion processes.6,7,8 In CKD, progressive loss of nephrons leads to compensatory hyperfiltration in remaining glomeruli, which initially maintains renal function but ultimately contributes to glomerular hypertension and further structural damage.9

The pathophysiology of CKD is complex and multifactorial, involving hemodynamic alterations, metabolic disturbances, oxidative stress, and chronic inflammation.10 Key histopathological features include glomerulosclerosis, tubular atrophy, interstitial fibrosis, and vascular rarefaction.11 These changes are mediated by activation of the renin–angiotensin–aldosterone system (RAAS), increased production of pro-inflammatory cytokines, and accumulation of reactive oxygen species (ROS), all of which accelerate renal injury and fibrosis.12 Persistent albuminuria and declining GFR are hallmarks of disease progression and are closely linked to cardiovascular morbidity and mortality.13

Despite advances in supportive care, including blood pressure control, glycemic management, and RAAS inhibition, the progression of CKD often remains unavoidable in many patients. This has prompted interest in novel therapeutic strategies that target renal pathophysiology at multiple levels. In this context, sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a breakthrough class of drugs with demonstrated renoprotective and cardioprotective benefits beyond their glucose-lowering effects.14

Empagliflozin, a selective SGLT2 inhibitor, acts primarily in the proximal renal tubules by reducing glucose and sodium reabsorption, leading to osmotic diuresis and improved tubuloglomerular feedback.15 This mechanism results in reduced intraglomerular pressure and attenuation of hyperfiltration injury. In addition, empagliflozin has been shown to exert anti-inflammatory, antioxidative, and antifibrotic effects, thereby slowing the progression of structural kidney damage. Its pleiotropic actions make it a promising therapeutic agent in both diabetic and non-diabetic CKD.

Given the intricate relationship between renal anatomy, physiology, and biochemical pathways involved in CKD progression, a comprehensive understanding of these mechanisms is essential for optimizing treatment strategies. This review integrates the structural and functional aspects of the kidney with the pathological processes of CKD and critically evaluates the pharmacological role of empagliflozin as a renoprotective agent in modern clinical practice

Study Design This study was designed as an experimental, mechanistic, and pharmacological evaluation of empagliflozin in chronic kidney disease (CKD), integrating in vivo, biochemical, and histopathological approaches. A controlled laboratory-based animal model of CKD was used to simulate progressive renal injury and assess the renoprotective effects of empagliflozin. Experimental Animals Adult male Wistar rats (180–220 g) were selected and maintained under standard laboratory conditions (12-hour light/dark cycle, controlled temperature, and free access to food and water). Animals were acclimatized for one week prior to experimentation. All procedures were conducted in accordance with institutional ethical guidelines for animal research. Induction of Chronic Kidney Disease CKD was induced using adenine administration (0.25–0.75% w/w mixed in standard diet) for a defined period to produce progressive tubulointerstitial injury, mimicking human CKD pathology. This model was chosen due to its ability to replicate key features such as tubular atrophy, interstitial fibrosis, elevated serum creatinine, and reduced glomerular filtration. Experimental Groups Animals were randomly divided into the following groups: • Group I (Control): Received standard diet without intervention • Group II (CKD model): Received adenine diet only • Group III (CKD + Empagliflozin low dose): CKD induced + empagliflozin (10 mg/kg/day) • Group IV (CKD + Empagliflozin high dose): CKD induced + empagliflozin (25 mg/kg/day) Treatment was administered orally once daily for a defined therapeutic period after CKD induction. Assessment of Renal Function Renal functional parameters were evaluated through serum and urine analysis. Blood samples were collected via retro-orbital puncture for estimation of: • Serum creatinine • Blood urea nitrogen (BUN) • Uric acid • Estimated glomerular filtration rate (eGFR) Urine samples were analyzed for • Albumin excretion rate • Urinary creatinine • Albumin-to-creatinine ratio (ACR) Biochemical and Molecular Analysis To evaluate the biochemical mechanisms of empagliflozin, renal tissue homogenates were prepared and analyzed for: • Oxidative stress markers: malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) • Inflammatory cytokines: TNF-α, IL-6, and CRP • Fibrotic markers: TGF-β1 and collagen deposition indices. Histopathological Examination Kidney tissues were fixed in 10% formalin, processed, and stained using hematoxylin and eosin (H&E) for general morphology and Masson’s trichrome staining for fibrosis assessment. Structural changes including glomerulosclerosis, tubular degeneration, and interstitial fibrosis were scored semi-quantitatively under light microscopy. Immunohistochemical Analysis Expression of key renal injury and fibrosis-related proteins such as TGF-β1, NF-κB, and caspase-3 was evaluated using immunohistochemistry to determine the molecular impact of empagliflozin on inflammatory and apoptotic pathways. Statistical Analysis All data were expressed as mean ± standard deviation (SD). Statistical comparisons between groups were performed using one-way ANOVA followed by post hoc Tukey’s test. A p-value < 0.05 was considered statistically significant. GraphPad Prism software was used for analysis and graphical representation.

Table 1: Effect of Empagliflozin on Renal Function Parameters

Table 2: Effect on Urinary Markers

Table 3: Oxidative Stress Markers in Renal Tissue

Table 4: Inflammatory Cytokines

Table 5: Fibrotic Markers

Table 6: Histopathological and Molecular Findings

Chronic kidney disease (CKD) represents a progressive and irreversible clinical condition characterized by structural destruction of renal parenchyma and functional decline in glomerular filtration. In the present experimental study, adenine-induced CKD successfully reproduced key features of human renal disease, including elevated serum creatinine, blood urea nitrogen (BUN), uric acid, albuminuria, oxidative stress, inflammation, and histological evidence of glomerulosclerosis

and interstitial fibrosis. These findings confirm the validity of the model for evaluating potential renoprotective agents.

Administration of empagliflozin demonstrated a significant improvement in renal functional parameters, as evidenced by reduced serum creatinine and BUN levels along with restoration of eGFR. These improvements can be attributed primarily to the drug’s ability to modulate intraglomerular hemodynamics. By inhibiting sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule, empagliflozin enhances sodium delivery to the macula densa, thereby restoring tubuloglomerular feedback. This mechanism leads to afferent arteriolar vasoconstriction, reduction in glomerular hyperfiltration, and ultimately decreased intraglomerular pressure, which is a central driver of CKD progression.

A notable finding of this study is the significant reduction in albuminuria and albumin-to-creatinine ratio (ACR) following empagliflozin treatment. Albuminuria is not only a marker of glomerular damage but also an active contributor to tubular inflammation and fibrosis. The observed reduction suggests restoration of glomerular filtration barrier integrity and improved tubular handling of filtered proteins. These effects are consistent with previous mechanistic evidence suggesting that SGLT2 inhibition reduces glomerular stress and protein overload in proximal tubules.

Oxidative stress plays a central role in CKD progression through the accumulation of reactive oxygen species (ROS), leading to lipid peroxidation and mitochondrial dysfunction. In this study, CKD animals showed elevated malondialdehyde (MDA) levels with concomitant depletion of antioxidant enzymes such as SOD, CAT, and GPx. Empagliflozin significantly reversed these alterations, indicating strong antioxidant potential. This effect may be linked to improved mitochondrial efficiency, reduced glucotoxicity, and decreased NADPH oxidase activity, thereby limiting ROS generation.

Inflammation is another critical driver of renal injury in CKD. The elevated levels of TNF-α, IL-6, and CRP observed in the CKD group reflect activation of pro-inflammatory signaling pathways, particularly NF-κB-mediated transcriptional responses. Empagliflozin markedly reduced these cytokines, suggesting suppression of chronic inflammatory signaling. Downregulation of NF-κB expression observed in immunohistochemical analysis further supports the anti-inflammatory role of empagliflozin at the molecular level.

Fibrosis represents the final common pathway of CKD progression and is largely mediated by TGF-β1 signaling, which promotes extracellular matrix accumulation and collagen deposition. In the present study, CKD animals exhibited marked upregulation of TGF-β1 and extensive interstitial fibrosis. Empagliflozin significantly reduced both TGF-β1 expression and collagen accumulation, indicating inhibition of fibrogenic signaling pathways. This antifibrotic effect may be secondary to reduced inflammation, decreased tubular injury, and attenuation of epithelial-to-mesenchymal transition.

Histopathological findings further corroborated the biochemical and molecular data. CKD-induced structural damage, including glomerulosclerosis, tubular atrophy, and interstitial inflammation, was significantly attenuated by empagliflozin treatment. Preservation of renal architecture in treated groups suggests that empagliflozin not only improves functional biomarkers but also provides structural protection against progressive nephron loss.

Apoptotic signaling, as evidenced by increased caspase-3 expression in CKD animals, indicates ongoing renal cell injury and loss. Empagliflozin reduced caspase-3 expression, suggesting anti-apoptotic effects that may be mediated through improved mitochondrial function and reduced oxidative stress.

Overall, the findings of this study demonstrate that empagliflozin exerts multifaceted renoprotective effects through hemodynamic, metabolic, anti-inflammatory, antioxidant, and antifibrotic mechanisms. The dose-dependent response observed across most parameters further strengthens its therapeutic relevance in CKD management. Importantly, these results support the concept that SGLT2 inhibition provides kidney protection beyond glycemic control, making empagliflozin a promising pharmacological agent for both diabetic and non-diabetic CKD,

Empagliflozin significantly attenuates CKD progression by targeting multiple interconnected pathological pathways, thereby preserving renal structure and function. These findings highlight its potential role as a cornerstone therapy in modern nephroprotection strategies.

1. Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, Meribole ES, Lawal SO, Okenwa CJ, Okafor GC, Umeh ED. Comprehensive review of current management guidelines of chronic kidney disease. Medicine. 2023 Jun 9;102(23):e33984.
2. Yan MT, Chao CT, Lin SH. Chronic kidney disease: strategies to retard progression. International journal of molecular sciences. 2021 Sep 18;22(18):10084.
3. Ahmed K, Dubey MK, Dubey S, Pandey DK. Chronic kidney disease: Causes, treatment, management, and future scope. InComputational Intelligence for Genomics Data 2025 Jan 1 (pp. 99-111). Academic Press.
4. Samara WN. Calcified Carotid Artery Atheromas on Panoramic Radiographs and CT Scans of Head and Neck Cancer Patients.
5. Haque AE, Razzaque MS. Specialty grand challenge: existing issues and emerging frontiers in renal endocrinology. Frontiers in Endocrinology. 2025 Jul 17;16:1651141.
6. Carswell C, O'Neil S. Applied anatomy and physiology, the kidney disease process, and kidney investigations. Renal Nursing: Care and Management of People with Kidney Disease. 2024 Sep 16:14-51.
7. Gallardo PA, Vio CP. Functional anatomy of the kidney. InRenal Physiology and Hydrosaline Metabolism 2022 Sep 23 (pp. 7-28). Cham: Springer International Publishing.
8. Beena V. Excretory Physiology. InTextbook of Veterinary Physiology 2023 Sep 1 (pp. 213-231). Singapore: Springer Nature Singapore.
9. Romagnani P, Agarwal R, Chan JC, Levin A, Kalyesubula R, Karam S, Nangaku M, Rodríguez-Iturbe B, Anders HJ. Chronic kidney disease. Nature reviews Disease primers. 2025 Jan 30;11(1):8.
10. Qasim H, Hayajneh A, Khattab K, Leoni ML, Varrassi G. Histopathology of Diabetic Nephropathy: Beyond Glomerular Basement Membrane Thickening. Cureus. 2025 Sep 29;17(9).
11. Arendshorst WJ, Vendrov AE, Kumar N, Ganesh SK, Madamanchi NR. Oxidative stress in kidney injury and hypertension. Antioxidants. 2024 Nov 27;13(12):1454.
12. Frąk W, Dąbek B, Balcerczyk-Lis M, Motor J, Radzioch E, Młynarska E, Rysz J, Franczyk B. Role of uremic toxins, oxidative stress, and renal fibrosis in chronic kidney disease. Antioxidants. 2024 Jun 3;13(6):687.
13. Romero-Gonzalez G, Rodriguez-Chitiva N, Canameras C, Paul-Martinez J, Urrutia-Jou M, Troya M, Soler-Majoral J, Graterol Torres F, Sanchez-Baya M, Calabia J, Bover J. Albuminuria, forgotten no more: underlining the emerging role in cardiorenal crosstalk. Journal of clinical medicine. 2024 Jan;13(3):777.
14. Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R, Marfella R, Docimo G, Lettieri M. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. International Journal of Molecular Sciences. 2022 Mar 26;23(7):3651.
15. Lee YH, Lim S, Davies MJ. Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors. Nature Reviews Endocrinology. 2025 Dec;21(12):783-98.